Published in Nature on April 03, 2008
Molecular Profiling of Colorectal Cancer | NCT04863768
Melanoma: Genomic Profiles, Molecular Markers and Therapeutic Implications | NCT05119829
International network of cancer genome projects. Nature (2010) 20.35
Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst (2008) 8.14
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 6.38
An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 5.47
MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell (2009) 4.47
Systems medicine: the future of medical genomics and healthcare. Genome Med (2009) 3.85
IntOGen: integration and data mining of multidimensional oncogenomic data. Nat Methods (2010) 3.63
The UCSC Cancer Genomics Browser: update 2011. Nucleic Acids Res (2010) 3.37
Making sense of cancer genomic data. Genes Dev (2011) 3.01
A network model of a cooperative genetic landscape in brain tumors. JAMA (2009) 2.86
The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell (2011) 2.83
Mutational spectra of human cancer. Hum Genet (2009) 2.26
Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. Proc Natl Acad Sci U S A (2010) 2.07
Organocatalytic removal of formaldehyde adducts from RNA and DNA bases. Nat Chem (2015) 2.01
MicroRNA-17~92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways. EMBO J (2013) 2.01
A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. Cancer Res (2011) 1.89
Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas. JAMA (2009) 1.81
Mechanisms and insights into drug resistance in cancer. Front Pharmacol (2013) 1.70
Cancer gene discovery in hepatocellular carcinoma. J Hepatol (2010) 1.68
A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat Chem Biol (2011) 1.65
Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat Rev Cancer (2010) 1.54
Regulation of G1 Cell Cycle Progression: Distinguishing the Restriction Point from a Nutrient-Sensing Cell Growth Checkpoint(s). Genes Cancer (2010) 1.53
Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med (2011) 1.52
Invasive three-dimensional organotypic neoplasia from multiple normal human epithelia. Nat Med (2010) 1.52
Efficient acquisition of dual metastasis organotropism to bone and lung through stable spontaneous fusion between MDA-MB-231 variants. Proc Natl Acad Sci U S A (2009) 1.45
Functional genomic analysis of chromosomal aberrations in a compendium of 8000 cancer genomes. Genome Res (2012) 1.39
Mig-6 controls EGFR trafficking and suppresses gliomagenesis. Proc Natl Acad Sci U S A (2010) 1.38
Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res (2010) 1.28
A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker. Mol Cell Proteomics (2011) 1.27
Managing drug resistance in cancer: lessons from HIV therapy. Nat Rev Cancer (2012) 1.19
G-DOC: a systems medicine platform for personalized oncology. Neoplasia (2011) 1.18
RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1. Nature (2013) 1.18
Predictive and prognostic molecular markers for cancer medicine. Ther Adv Med Oncol (2010) 1.18
8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis. PLoS One (2009) 1.14
Patient-centric trials for therapeutic development in precision oncology. Nature (2015) 1.14
Qualitative thematic analysis of consent forms used in cancer genome sequencing. BMC Med Ethics (2011) 1.13
Cardiac signaling genes exhibit unexpected sequence diversity in sporadic cardiomyopathy, revealing HSPB7 polymorphisms associated with disease. J Clin Invest (2009) 1.10
Chromothripsis-like patterns are recurring but heterogeneously distributed features in a survey of 22,347 cancer genome screens. BMC Genomics (2014) 1.08
Multiplexed DNA repair assays for multiple lesions and multiple doses via transcription inhibition and transcriptional mutagenesis. Proc Natl Acad Sci U S A (2014) 1.06
Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia. Leukemia (2012) 1.05
Toward better benchmarking: challenge-based methods assessment in cancer genomics. Genome Biol (2014) 1.05
High resolution genome-wide analysis of chromosomal alterations in Burkitt's lymphoma. PLoS One (2009) 1.03
Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses. PLoS One (2012) 1.01
Somatic variation and cancer: therapies lost in the mix. Hum Genet (2011) 0.99
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med (2015) 0.98
Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol (2011) 0.97
Cancer gene prioritization by integrative analysis of mRNA expression and DNA copy number data: a comparative review. Brief Bioinform (2012) 0.96
The genomic architecture of sporadic heart failure. Circ Res (2011) 0.95
Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer. EMBO Mol Med (2011) 0.95
From cancer genomes to cancer models: bridging the gaps. EMBO Rep (2009) 0.95
A computational procedure to identify significant overlap of differentially expressed and genomic imbalanced regions in cancer datasets. Nucleic Acids Res (2009) 0.94
The role of gene expression profiling in early-stage non-small cell lung cancer. J Thorac Dis (2010) 0.93
Genomics: the breast cancer landscape. Nature (2012) 0.91
Knowledge boosting: a graph-based integration approach with multi-omics data and genomic knowledge for cancer clinical outcome prediction. J Am Med Inform Assoc (2014) 0.87
Protein modifications as potential biomarkers in breast cancer. Biomark Insights (2009) 0.87
Epigenetic alterations in inflammatory bowel disease and cancer. Intest Res (2015) 0.87
Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway. Adv Urol (2012) 0.86
Intra-relation reconstruction from inter-relation: miRNA to gene expression. BMC Syst Biol (2013) 0.86
Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation:a systematic review and meta-analysis. Br J Radiol (2012) 0.86
Omics Profiling in Precision Oncology. Mol Cell Proteomics (2016) 0.85
Proteomic approaches in biomarker discovery: new perspectives in cancer diagnostics. ScientificWorldJournal (2014) 0.85
A novel potent tumour promoter aberrantly overexpressed in most human cancers. Sci Rep (2011) 0.85
Breast cancer genomes--form and function. Curr Opin Genet Dev (2010) 0.85
Integrated genomics of ovarian xenograft tumor progression and chemotherapy response. BMC Cancer (2011) 0.84
Integrative analysis of somatic mutations altering microRNA targeting in cancer genomes. PLoS One (2012) 0.84
Comparative oncogenomic analysis of copy number alterations in human and zebrafish tumors enables cancer driver discovery. PLoS Genet (2013) 0.84
An algorithm for classifying tumors based on genomic aberrations and selecting representative tumor models. BMC Med Genomics (2010) 0.83
Progenetix: 12 years of oncogenomic data curation. Nucleic Acids Res (2013) 0.82
Incorporating inter-relationships between different levels of genomic data into cancer clinical outcome prediction. Methods (2014) 0.81
Mammalian NADH:ubiquinone oxidoreductase (Complex I) and nicotinamide nucleotide transhydrogenase (Nnt) together regulate the mitochondrial production of H₂O₂--implications for their role in disease, especially cancer. J Bioenerg Biomembr (2011) 0.81
[High-throughput sequencing of frozen and paraffin-embedded tumor and normal tissue]. Pathologe (2010) 0.81
Prediction and prioritization of rare oncogenic mutations in the cancer Kinome using novel features and multiple classifiers. PLoS Comput Biol (2014) 0.80
Identification of potential glycan cancer markers with sialic acid attached to sialic acid and up-regulated fucosylated galactose structures in epidermal growth factor receptor secreted from A431 cell line. Mol Cell Proteomics (2013) 0.80
BRCC2 inhibits breast cancer cell growth and metastasis in vitro and in vivo via downregulating AKT pathway. Cell Death Dis (2013) 0.80
Toward personalized cancer nanomedicine - past, present, and future. Integr Biol (Camb) (2013) 0.80
Quantitative analysis of p53 expression in human normal and cancer tissue microarray with global normalization method. Int J Clin Exp Pathol (2011) 0.79
The 21st century hepatologist and a systems biology based approach to liver diseases. Hepatology (2008) 0.79
Model-based clustering of array CGH data. Bioinformatics (2009) 0.79
Identification of novel driver tumor suppressors through functional interrogation of putative passenger mutations in colorectal cancer. Int J Cancer (2012) 0.78
Human induced pluripotent stem cells from basic research to potential clinical applications in cancer. Biomed Res Int (2013) 0.78
Integrative genomic approaches to understanding cancer. Biochim Biophys Acta (2009) 0.78
Latent Feature Decompositions for Integrative Analysis of Multi-Platform Genomic Data. IEEE/ACM Trans Comput Biol Bioinform (2014) 0.78
Capture-based next-generation sequencing reveals multiple actionable mutations in cancer patients failed in traditional testing. Mol Genet Genomic Med (2016) 0.77
Loss of chromosome 9p21 and decreased p16 expression correlate with malignant gastrointestinal stromal tumor. World J Gastroenterol (2010) 0.77
Abnormal expression of an ADAR2 alternative splicing variant in gliomas downregulates adenosine-to-inosine RNA editing. Acta Neurochir (Wien) (2014) 0.76
Aberrant DNA methylations in chondrosarcoma. Epigenomics (2016) 0.76
Musings on genome medicine: cancer genetics and the promise of effective treatment. Genome Med (2009) 0.75
Modulating Effect of Hypnea musciformis (Red Seaweed) on Lipid Peroxidation, Antioxidants and Biotransforming Enzymes in 7,12-Dimethylbenz (a) Anthracene Induced Mammary Carcinogenesis in Experimental Animals. Pharmacognosy Res (2017) 0.75
Polygenic in vivo validation of cancer mutations using transposons. Genome Biol (2014) 0.75
Identifying Cancer Driver Genes Using Replication-Incompetent Retroviral Vectors. Cancers (Basel) (2016) 0.75
X-linked FHL1 as a novel therapeutic target for head and neck squamous cell carcinoma. Oncotarget (2016) 0.75
Multivariate Boosting for Integrative Analysis of High-Dimensional Cancer Genomic Data. Cancer Inform (2015) 0.75
Confident predictability: identifying reliable gene expression patterns for individualized tumor classification using a local minimax kernel algorithm. BMC Med Genomics (2011) 0.75
Novel cancerization marker, TP53, and its role in distinguishing normal tissue adjacent to cancerous tissue from normal tissue adjacent to benign tissue. World J Surg Oncol (2012) 0.75
Identifying driver genes in cancer by triangulating gene expression, gene location, and survival data. Cancer Inform (2015) 0.75
Ribonucleic acid (RNA) biosynthesis in human cancer. Cancer Cell Int (2015) 0.75
Non-Invasive Detection of Esophageal Cancer using Genetic Changes in Circulating Cell-Free DNA. Avicenna J Med Biotechnol (2012) 0.75
Registered report: Diverse somatic mutation patterns and pathway alterations in human cancers. Elife (2016) 0.75
Genome sequencing in microfabricated high-density picolitre reactors. Nature (2005) 150.21
The hallmarks of cancer. Cell (2000) 113.05
A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J Mol Biol (1975) 90.35
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet (2008) 43.63
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (1994) 36.53
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
Paired-end mapping reveals extensive structural variation in the human genome. Science (2007) 30.46
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Accurate multiplex polony sequencing of an evolved bacterial genome. Science (2005) 20.91
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
Identification of the breast cancer susceptibility gene BRCA2. Nature (1996) 17.14
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (1990) 16.68
Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science (1992) 16.38
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
Multiplex amplification of large sets of human exons. Nat Methods (2007) 15.11
Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer (2007) 14.84
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature (2007) 10.98
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet (2004) 10.92
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (1985) 9.12
Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res (2005) 8.69
Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet (2000) 8.58
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol (2006) 7.76
End-sequence profiling: sequence-based analysis of aberrant genomes. Proc Natl Acad Sci U S A (2003) 7.70
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A (2001) 7.51
Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature (2000) 7.28
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res (2006) 7.18
Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution. Genome Res (2007) 6.91
BRCA1 mutations in primary breast and ovarian carcinomas. Science (1994) 6.81
Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science (1985) 6.56
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 6.55
The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature (1985) 6.23
PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet (1999) 6.18
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature (2007) 5.65
A genetic screen for candidate tumor suppressors identifies REST. Cell (2005) 5.61
The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov (2006) 5.11
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat (2008) 4.84
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell (2006) 4.68
Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. Sci Am (2007) 4.66
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell (2006) 4.52
Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet (2005) 4.33
Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev (2006) 4.24
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell (2006) 3.93
A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci U S A (1985) 3.80
Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet (2003) 3.70
Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol (2008) 3.16
INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res (2005) 3.08
Activating Notch1 mutations in mouse models of T-ALL. Blood (2005) 3.08
Telomere dysfunction provokes regional amplification and deletion in cancer genomes. Cancer Cell (2002) 3.06
DNA sequence determination by hybridization: a strategy for efficient large-scale sequencing. Science (1993) 2.76
Retroviral insertional mutagenesis: past, present and future. Oncogene (2005) 2.63
A comparison of DNA copy number profiling platforms. Cancer Res (2007) 2.63
Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst (1995) 2.62
Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov (2007) 2.40
Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol (2001) 2.20
Chop it, ChIP it, check it: the current status of chromatin immunoprecipitation. Front Biosci (2008) 2.15
Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet (1995) 2.11
Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol (2004) 1.83
The role of chromosome translocations in leukemogenesis. Semin Hematol (1999) 1.76
Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. Cancer (2004) 1.75
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis (2005) 1.61
Where next for gefitinib in patients with lung cancer? Lancet Oncol (2006) 1.58
Digital karyotyping. Nat Protoc (2007) 1.58
Understanding the cell cycle. Nat Med (1998) 1.43
DNA-dependent protein kinase catalytic subunit is not required for dysfunctional telomere fusion and checkpoint response in the telomerase-deficient mouse. Mol Cell Biol (2006) 1.39
Drosophila Myc is oncogenic in mammalian cells and plays a role in the diminutive phenotype. Proc Natl Acad Sci U S A (1997) 1.37
Mice without telomerase: what can they teach us about human cancer? Nat Med (2000) 1.33
The genetics of programmed cell death in the nematode Caenorhabditis elegans. Cold Spring Harb Symp Quant Biol (1994) 1.23
Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol (2000) 1.23
Discovery of the Philadelphia chromosome: a personal perspective. J Clin Invest (2007) 1.21
Epigenomic profiling using microarrays. Biotechniques (2003) 1.21
Copy number aberrations in mouse breast tumors reveal loci and genes important in tumorigenic receptor tyrosine kinase signaling. Cancer Res (2005) 1.20
HKI-272 in non small cell lung cancer. Clin Cancer Res (2007) 1.07
Molecular markers of prostate cancer. Urol Oncol (2006) 1.00
An arrayed human not I-EcoRV boundary library as a tool for RLGS spot analysis. DNA Res (1997) 0.89
An AscI boundary library for the studies of genetic and epigenetic alterations in CpG islands. Genome Res (2002) 0.84
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell (2006) 16.05
Induction of tumors in mice by genomic hypomethylation. Science (2003) 8.86
An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res (2004) 8.86
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A (2004) 7.96
End-sequence profiling: sequence-based analysis of aberrant genomes. Proc Natl Acad Sci U S A (2003) 7.70
Chromosome aberrations in solid tumors. Nat Genet (2003) 7.01
A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 6.09
The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol (2007) 5.81
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet (2005) 4.70
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med (2004) 4.69
Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A (2011) 4.55
In situ analyses of genome instability in breast cancer. Nat Genet (2004) 4.32
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med (2011) 4.10
Restriction of receptor movement alters cellular response: physical force sensing by EphA2. Science (2010) 3.72
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res (2010) 3.53
Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer (2006) 3.34
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics (2010) 3.25
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res (2009) 3.14
Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A (2011) 3.10
Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A (2005) 2.96
Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res (2007) 2.94
Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res (2006) 2.86
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol (2012) 2.85
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat (2011) 2.73
Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther (2006) 2.55
Modeling precision treatment of breast cancer. Genome Biol (2013) 2.42
Temporal dissection of tumorigenesis in primary cancers. Cancer Discov (2011) 2.40
Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res (2006) 2.37
HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat (2009) 2.34
A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell (2005) 2.27
Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Neuro Oncol (2009) 2.23
Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res (2011) 2.12
Decoding the fine-scale structure of a breast cancer genome and transcriptome. Genome Res (2006) 2.09
Frequent silencing of low density lipoprotein receptor-related protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in esophageal squamous cell carcinoma. Cancer Res (2004) 1.98
Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res (2002) 1.96
A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov (2012) 1.87
Exon-level microarray analyses identify alternative splicing programs in breast cancer. Mol Cancer Res (2010) 1.84
A human breast cell model of preinvasive to invasive transition. Cancer Res (2008) 1.79
Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res (2007) 1.79
Analysis of molecular inversion probe performance for allele copy number determination. Genome Biol (2007) 1.78
Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat Chem Biol (2013) 1.75
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell (2013) 1.73
Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet (2002) 1.70
Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Res (2003) 1.67
Cellular effect of high doses of silica-coated quantum dot profiled with high throughput gene expression analysis and high content cellomics measurements. Nano Lett (2006) 1.63
Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice. Cancer Cell (2007) 1.59
Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer (2007) 1.57
Invariant delineation of nuclear architecture in glioblastoma multiforme for clinical and molecular association. IEEE Trans Med Imaging (2012) 1.53
Molecular characterization of the cytotoxic mechanism of multiwall carbon nanotubes and nano-onions on human skin fibroblast. Nano Lett (2005) 1.53
Rbfox proteins regulate alternative mRNA splicing through evolutionarily conserved RNA bridges. Nat Struct Mol Biol (2013) 1.49
CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res (2013) 1.48
Molecular predictors of 3D morphogenesis by breast cancer cell lines in 3D culture. PLoS Comput Biol (2010) 1.46
A sequence-based survey of the complex structural organization of tumor genomes. Genome Biol (2008) 1.45
A nanoplasmonic molecular ruler for measuring nuclease activity and DNA footprinting. Nat Nanotechnol (2006) 1.44
Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res (2009) 1.43
Picomolar sensitivity MRI and photoacoustic imaging of cobalt nanoparticles. Proc Natl Acad Sci U S A (2009) 1.43
EGFR Intron 1 polymorphism in Asian Populations and its correlation with EGFR gene expression and amplification in breast tumor tissues. Cancer Biol Ther (2006) 1.42
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther (2006) 1.41
Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. Cancer Res (2007) 1.34
A screen for genes that suppress loss of contact inhibition: identification of ING4 as a candidate tumor suppressor gene in human cancer. Proc Natl Acad Sci U S A (2004) 1.33
ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet (2008) 1.33
Genome amplification of chromosome 20 in breast cancer. Breast Cancer Res Treat (2003) 1.29
High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays. BMC Med Genomics (2009) 1.29
The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer. Breast Cancer Res (2010) 1.29
Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling. Proc Natl Acad Sci U S A (2013) 1.27
Morphometic analysis of TCGA glioblastoma multiforme. BMC Bioinformatics (2011) 1.26
Integrated analysis of breast cancer cell lines reveals unique signaling pathways. Genome Biol (2009) 1.25
COMPARISON OF SPARSE CODING AND KERNEL METHODS FOR HISTOPATHOLOGICAL CLASSIFICATION OF GLIOBASTOMA MULTIFORME. Proc IEEE Int Symp Biomed Imaging (2011) 1.24
A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047. BMC Med (2009) 1.22
Copy number aberrations in mouse breast tumors reveal loci and genes important in tumorigenic receptor tyrosine kinase signaling. Cancer Res (2005) 1.20
Biallelic inactivation of the thyroid hormone receptor beta1 gene in early stage breast cancer. Cancer Res (2002) 1.19
Identification of PADI2 as a potential breast cancer biomarker and therapeutic target. BMC Cancer (2012) 1.18
Bayesian inference of signaling network topology in a cancer cell line. Bioinformatics (2012) 1.17
Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers. Breast Cancer Res (2007) 1.15
What are we learning from the cancer genome? Nat Rev Clin Oncol (2012) 1.13
Quantum dots-based reverse phase protein microarray. Talanta (2005) 1.12
Multiple roles of the candidate oncogene ZNF217 in ovarian epithelial neoplastic progression. Int J Cancer (2007) 1.10
Array comparative genomic hybridization with cyanin cis-platinum-labeled DNAs. Biotechniques (2004) 1.09
c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells. Cancer Res (2013) 1.09
High-throughput method for analyzing methylation of CpGs in targeted genomic regions. Proc Natl Acad Sci U S A (2010) 1.08
Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERα-positive breast cancer. Mol Cancer Res (2011) 1.08
Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer. Clin Cancer Res (2010) 1.06
The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. Cancer Discov (2012) 1.06
Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomarkers Prev (2006) 1.06
Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis. Mol Oncol (2008) 1.04
Rab25 increases cellular ATP and glycogen stores protecting cancer cells from bioenergetic stress. EMBO Mol Med (2012) 1.03
A fluid membrane-based soluble ligand-display system for live-cell assays. Chembiochem (2006) 1.03
Qdot nanobarcodes for multiplexed gene expression analysis. Nano Lett (2006) 1.02
Lectin chromatography/mass spectrometry discovery workflow identifies putative biomarkers of aggressive breast cancers. J Proteome Res (2012) 1.01
A primer on regression methods for decoding cis-regulatory logic. PLoS Comput Biol (2009) 1.00
Genetic differences in transcript responses to low-dose ionizing radiation identify tissue functions associated with breast cancer susceptibility. PLoS One (2012) 1.00
The role of p53 in suppression of KSHV cyclin-induced lymphomagenesis. Cancer Res (2004) 0.98
Loss of cell-surface laminin anchoring promotes tumor growth and is associated with poor clinical outcomes. Cancer Res (2012) 0.98
Integrating biological knowledge into variable selection: an empirical Bayes approach with an application in cancer biology. BMC Bioinformatics (2012) 0.98